发明名称 Near full-genome assay of HCV drug resistance
摘要 The invention relates to assays for characterization of genotypic mutations of Hepatitis C Virus (HCV) showing a resistance to anti-HCV drugs.
申请公布号 US8911934(B2) 申请公布日期 2014.12.16
申请号 US200812739648 申请日期 2008.10.31
申请人 Debiopharm SA;Katholieke Universiteit Leuven 发明人 Vuagniaux Grégoire;Dumont Jean-Maurice;Snoeck Joke;Van Dooren Sonia;Vandamme Anne-Mieke
分类号 C12Q1/70;C07H21/00 主分类号 C12Q1/70
代理机构 Hoffmann & Baron, LLP 代理人 Hoffmann & Baron, LLP
主权项 1. An assay for identifying a mutation in the genome of an HCV present in a sample, the assay comprising the sequential steps of: a) extraction of viral RNA from the sample containing the HCV; b) determination of genotype and subtype of the HCV; c) synthesis of partial cDNAs of the genome of the HCV in three separate reverse transcription reactions, the first reverse transcription reaction initiated from a first outer antisense primer selected to specifically hybridize to a sequence in the 3′UTR of a prototype HCV genome of the same genotype and subtype, the second reverse transcription reaction initiated from a second outer antisense primer selected to specifically hybridize to a sequence in the NS4B-NS5A region of the genome of the prototype HCV and the third reverse transcription reaction initiated from a third outer antisense primer selected to specifically hybridize to a sequence in the NS2 region of the genome of the prototype HCV; d) second strand synthesis and amplification of the partial cDNAs of step c) in three separate PCR reactions, the first PCR reaction comprising an aliquot of the first reverse transcription reaction, the first outer antisense primer and a first outer sense primer selected to specifically hybridize to a complementary sequence in the NS4B-NS5A region of the genome of the prototype HCV, the second PCR reaction comprising an aliquot of the second reverse transcription reaction, the second outer antisense primer and a second outer sense primer selected to specifically hybridize to a complementary sequence in the NS2 region of the genome of the prototype HCV, and the third PCR reaction comprising an aliquot of the third reverse transcription reaction, the third outer antisense primer and a third outer sense primer selected to specifically hybridize to a complementary sequence in the 5′UTR region of the genome of the prototype HCV, wherein the second outer antisense primer hybridizes to a sequence in the NS4B-NS5A region of the genome of the prototype HCV that is located 3′ to the region that is complementary to the first outer sense primer and wherein the third outer antisense primer hybridizes to a sequence in the NS2 region of the genome of the prototype HCV that is located 3′ to the region that is complementary to the second outer sense primer; e) further amplification of the partial cDNAs of step d) in three separate nested PCR reactions, the first nested PCR reaction comprising an aliquot of the first PCR reaction and first inner antisense and sense primers, the second nested PCR reaction comprising an aliquot of the second PCR reaction and second inner antisense and sense primers, and the third nested PCR reaction comprising an aliquot of the third PCR reaction and third inner antisense and sense primers, wherein the inner primers do not overlap the outer primers, the second inner antisense primer hybridizes to a sequence in the NS4B-NS5A region of the genome of the prototype HCV that is located 3′ to the region that is complementary to the first inner sense primer and the third inner antisense primer hybridizes to a sequence in the NS2 region of the genome of the prototype HCV that is located 3′ to the region that is complementary to the second inner sense primer; f) sequence analysis of the further amplified cDNAs of step e); and g) comparison of the sequences obtained from step f) with that of the prototype HCV.
地址 Lausanne CH